AMD3100 was the first CXCR4 inhibitor to receive FDA approval for its utility in bone marrow transplantation procedures and is currently approved by the FDA for the treatment of multiple myeloma and non-Hodgkin’s lymphoma [43, 44]. Here, CXCR4 is linked to plasma cell myeloma.